ロード中...
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
Dysregulation of Janus kinase (JAK)–signal transducer and activator of transcription signaling is central to the pathogenesis of myelofibrosis (MF). JAK2 inhibitor therapy in MF patients results in a rapid reduction of the degree of splenomegaly, yet the mechanism underlying this effect remains unkn...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224194/ https://ncbi.nlm.nih.gov/pubmed/25193869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558015 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|